A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases
Authors' conclusion
In a non-medical switch scenario of RMD patients, there was no evidence for a considerable difference in ABP retention rates over 6 months between comorbidity groups.
Study context
- Population
- Patients with inflammatory rheumatic musculoskeletal diseases (axSpA n = 68, RA n = 23, PsA n = 15) switching from originator adalimumab to ABP501 biosimilar, from October 2018 onwards
- Participants
- 111 patients
- Exposure
- Charlson Comorbidity Index (CCI) > 0 vs CCI = 0 in rheumatic musculoskeletal diseases (RMD) patients switched from originator ADA to ABP501 biosimilar
- Outcome
- ABP retention rate
- Follow-up
- 6 months
Methodological detailsroutine database, non-medical switch, Bayesian exponential regression
- Routine database
- Non-medical switch
- Bayesian exponential regression
Main finding
As reported in the abstract
Bayesian estimate of difference, adjusted for age, sex, disease subtype
−0.0689
95% CrI −0.2246 to 0.0234
By group
CCI > 0vs CCI = 0
Bayesian estimate of difference, adjusted for age, sex, disease subtype −0.0689 (95% CrI −0.2246 to 0.0234)
Observational data: associations, not effects.
Further findings
Treatment status after 6 months, all patients
- Continued ABP
- 74.8%
- Switched to another ADA biosimilar
- 10.8%
- Switched back to originator ADA
- 7.2%
- Switched to a different biologic
- 3.6%
- Dropped out
- 3.6%
Comorbidity at baseline
- CCI > 0
- 38%
- Cardiovascular comorbidities
- 40%
- Skin diseases
- 33%
- Gastrointestinal tract diseases
- 20%
- Eye diseases
- 20%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases. Arthritis Res Ther. Published 4 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →